Tremfya Self-Injector Approved
January 29, 2019 – The U.S. FDA has approved a new dosage form for Tremfya® (guselkumab), manufactured by Janssen Pharmaceuticals. The drug is now available in a prefilled subcutaneous (SC) self-injector.
First approved in 2017, Tremfya was previously available only in a prefilled syringe dosage form. The drug is indicated to treat moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. The recommended dose is 100mg taken once in the first week and then in Week 4. After these two loading doses, Tremfya is taken once every eight weeks.
Janssen has launched the self-injector dosage form at the same cost as the prefilled syringe dosage form.